IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review
Toxoplasma gondii infection can lead to severe disease in immunocompromised patients. Current systemic therapies in psoriasis rely on varying degrees of immunomodulation. Few studies have investigated the involvement of key cytokines targeted by these novel therapies (interleukins 23 and 17) in the...
Saved in:
| Main Authors: | J. Dagher, J. Ringuet |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-02-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X251320196 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review
by: José González Fernández, et al.
Published: (2025-05-01) -
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
by: Kristian Reich, et al.
Published: (2021-09-01) -
IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
by: Natalie Bourand, MS, et al.
Published: (2025-02-01) -
Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study
by: Federico Diotallevi, et al.
Published: (2025-01-01) -
IL-17 and IL-23 Inhibitors in Moderate to Severe Plaque Psoriasis as Part of Current Therapeutic Strategies
by: Ieva Saulite, et al.
Published: (2024-07-01)